OneDigital Funding Advisors LLC bought a brand new place in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) within the third quarter, based on its most up-to-date disclosure with the Securities and Alternate Fee. The institutional investor bought 3,260 shares of the biotechnology firm’s inventory, valued at roughly $206,000.
Different giant buyers have additionally lately added to or lowered their stakes within the firm. Blue Belief Inc. bought a brand new stake in shares of Viking Therapeutics within the third quarter price about $26,000. Thurston Springer Miller Herd & Titak Inc. bought a brand new stake in shares of Viking Therapeutics through the 2nd quarter valued at about $27,000. GAMMA Investing LLC lifted its place in Viking Therapeutics by 124.6% through the third quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology firm’s inventory price $28,000 after buying an extra 243 shares within the final quarter. Gilliland Jeter Wealth Administration LLC bought a brand new place in Viking Therapeutics within the third quarter price roughly $32,000. Lastly, Massmutual Belief Co. FSB ADV grew its place in Viking Therapeutics by 84.3% within the third quarter. Massmutual Belief Co. FSB ADV now owns 553 shares of the biotechnology firm’s inventory valued at $35,000 after buying an extra 253 shares within the final quarter. 76.03% of the inventory is presently owned by institutional buyers and hedge funds.
Viking Therapeutics Inventory Up 1.9 %
Shares of Viking Therapeutics inventory opened at $52.59 on Friday. The enterprise has a 50-day transferring common worth of $63.73 and a 200 day transferring common worth of $60.38. Viking Therapeutics, Inc. has a fifty-two week low of $11.55 and a fifty-two week excessive of $99.41. The agency has a market cap of $5.86 billion, a P/E ratio of -56.55 and a beta of 1.00.
Viking Therapeutics (NASDAQ:VKTX – Get Free Report) final posted its quarterly earnings outcomes on Wednesday, October twenty third. The biotechnology firm reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.02. Throughout the identical interval final yr, the enterprise earned ($0.23) EPS. As a bunch, equities analysis analysts anticipate that Viking Therapeutics, Inc. will publish -0.98 earnings per share for the present yr.
Wall Road Analysts Forecast Development
A lot of analysis companies have lately commented on VKTX. Oppenheimer reissued an “outperform” score and set a $138.00 goal worth on shares of Viking Therapeutics in a analysis report on Wednesday, September twenty fifth. Morgan Stanley reiterated an “chubby” score and issued a $105.00 worth goal on shares of Viking Therapeutics in a report on Thursday, September twelfth. William Blair restated an “outperform” score on shares of Viking Therapeutics in a analysis word on Wednesday. JPMorgan Chase & Co. initiated protection on Viking Therapeutics in a analysis report on Wednesday, September eleventh. They set an “chubby” score and a $80.00 goal worth on the inventory. Lastly, B. Riley assumed protection on Viking Therapeutics in a report on Friday. They issued a “purchase” score and a $109.00 worth goal for the corporate. One equities analysis analyst has rated the inventory with a promote score, ten have given a purchase score and two have given a powerful purchase score to the corporate. Based mostly on information from MarketBeat.com, the inventory presently has a mean score of “Purchase” and a consensus worth goal of $109.73.
Learn Our Newest Analysis Report on Viking Therapeutics
Insiders Place Their Bets
In associated information, CEO Brian Lian bought 216,130 shares of the agency’s inventory in a transaction that occurred on Friday, September twentieth. The inventory was bought at a mean worth of $70.83, for a complete worth of $15,308,487.90. Following the sale, the chief govt officer now owns 2,304,927 shares of the corporate’s inventory, valued at roughly $163,257,979.41. This commerce represents a 8.57 % lower of their place. The sale was disclosed in a doc filed with the SEC, which is accessible by way of this hyperlink. Additionally, Director J Matthew Singleton bought 10,300 shares of the corporate’s inventory in a transaction on Friday, September twentieth. The inventory was bought at a mean worth of $69.50, for a complete worth of $715,850.00. Following the transaction, the director now owns 9,500 shares of the corporate’s inventory, valued at roughly $660,250. The commerce was a 52.02 % lower of their possession of the inventory. The disclosure for this sale could be discovered right here. During the last three months, insiders have bought 371,117 shares of firm inventory valued at $27,140,009. Firm insiders personal 4.70% of the corporate’s inventory.
Viking Therapeutics Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical firm, focuses on the event of novel therapies for metabolic and endocrine problems. The corporate’s lead drug candidate is VK2809, an orally obtainable tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Part IIb medical trials to deal with sufferers with biopsy-confirmed non-alcoholic steatohepatitis, in addition to NAFLD.
Additional Studying
Need to see what different hedge funds are holding VKTX? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report).
Obtain Information & Scores for Viking Therapeutics Every day – Enter your e-mail tackle under to obtain a concise day by day abstract of the most recent information and analysts’ rankings for Viking Therapeutics and associated firms with MarketBeat.com’s FREE day by day e-mail publication.
